Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-07-03
2007-07-03
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S236100, C514S002600, C514S012200, C530S350000, C530S412000
Reexamination Certificate
active
10288734
ABSTRACT:
Methods for treating peptic ulcers and methods for treating gastroesophageal reflux disease by oral administration of a botulinum toxin.
REFERENCES:
patent: 4959384 (1990-09-01), Kraft et al.
patent: 5397770 (1995-03-01), Levin et al.
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5571116 (1996-11-01), Bolanos et al.
patent: 5670484 (1997-09-01), Binder
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6405732 (2002-06-01), Edwards et al.
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6521255 (2003-02-01), Vergez et al.
patent: 0 605 501 (1999-04-01), None
patent: 1 334 729 (2003-08-01), None
patent: WO 94/00481 (1994-01-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 01/58472 (2001-08-01), None
Ravich, William J.,Botulinum toxin for UES dysfunction: Therapy or poison?, Dysphagia, vol. 16, No. 3, Jul. 2001, pp. 168-170.
Rohrbach, S., et al.,Minimally invasive application of botulinum toxin type A in nasal hypersecretion, J. Oto-rhino-Laryngol 2001, Nov.-Dec.;63(6):382-4.
Olthoff, A., et al.,Botulinum Toxin type a induces apoptosis in nasal glands of guinea pigs, J. Oto-rhino-Laryngol 2001 Nov.; 110(11):1045-50.
Sanchez-Prieto, J.,Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J Biochem 1987 Jun.;165(3):675-81.
Schantz, E.J., et al.,Preparation and characterization of botulinum toxin type A for human treatment, Chap 3, pp. 41-49, Therapy with Botulinum Toxin, 1994, Ed. J. Jankovic, et al., Marcel Dekker, Inc. publisher.
Schantz, E.J., et al.,Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiol Rev 1992 Mar.;56(1):80-99.
Sloop, R.R., et al.,Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use, Neurology 1997 Jan.;48(1):249-53.
Wang, Z, et al.,Effects of botulinum toxin on gastric myoelectrical and vagal activities in dogs, Gastroenterology 2001 Apr.; 120 (5 Suppl 1):A-718.
Wiegand, H., et al.,I-Labelled botulinum A neurotoxin pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol, 1976;292:161-5.
Wiesel, P.H., et al.,Botulinum toxin for refractory postoperative pyloric spasm, Endoscopy 1997;29(2):132.
Spierings, ELH,Reflux-triggered migraine headache originating from the upper gum/teeth, Cephalalgia, 2002, 22, pp. 555-556.
Thumshirn, M.,Gastrointestinal motility disorders relevant to general practice, Schweiz Rundsch Med Prax, Oct. 16, 2002, 91(42), pp. 1741-1747 (abstract, translation from German).
Lew, M.F.,Analysis of the duration of efficacy of botulinum toxin type B in patients with cervical dystonia, Mov Disord, Sep. 2002, 17(5), p. 1142.
Albanese, A., et al.,The use of botulinum toxin on smooth muscles, Eur. J. Neurol 1995, Nov.; 2(supp 3): 29-33.
Bigalke, H., et al.,Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord, Naunyn Schmiedebergs Arch Pharmacol. 1981; 316:244-51.
Bigalke, H., et al.,Botulinum A Neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture, Brain Res 1985;360: 318-324.
Binz, T., et al.,The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins, y and Molecular Biology, Inc., vol. 265, No. 16, Jun. 5, 1990, pp. 9153-9158.
Boyd, R.S., et al.,The insulin secreting β-cell line, HlT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A, Mov Disord May 1995; 10(3):376.
Boyd, R.S., et al.,The effect of botulinum neurotoxin-B on insulin release from a β-cell line, Mov Disord May 1995;10(3):376.
Coffield, J.A., et al., p. 5,The site and mechanism of action of botulinum neurotoxin, Therapy with Botulinum Toxin, 1994, Ed. J. Jankovic, et al., Marcel Dekker, Inc. publisher.
Crowell, M.D., et al.,Botulinum Toxin reduces pyloric dysfunction in patients with diabetic gastroparesis, Gastroenterology 2002, Apr.; 122(4 Supp 1): A451-A452 (1 page).
Dabrowski, E., et al.,Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan Syndrome, Ann Neurol 2002 Sep.;52(3 Supp 1): S157 ABS 169.
Difazio, M., et al.,A focused review of the use of botulinum toxins for low back pain, Clin J Pain 2002;18(6 Suppl):S155-S162.
Dykstra, D., et al.,Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double blind study, Arch Phys Med Rehabil 1990 Jan.;71:24-26.
Eaker, E. Y, et al.,Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia, Dig Dis Sci 1997 Apr.:42(4):724-7.
Gui, D., et al.,Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats, Aliment Pharmacol Ther 2000, Jun.:14(6):829-834.
Gui, D. et al.,Effects of botulinum toxin on gastric emptying and digestive secretions. A possible tool for correction of obesity, Naunyn Schmiedebergs Arch Pharmacol 2002 Jun.:365(Suppl 2):R22.
Habermann, E., et al.,Journal of Neurochemistry, 51,522-527, 1988.
Habermann, E.,I-labeled Neurotoxin from clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord, Naunyn Schmiedebergs Arch Pharmacol 1974; 281:47-56.
Hanson, M.A., et al.,Structural view of botulinum neurotoxin in numerous functional states, Scientific and therapeutic aspects of botulinum toxin, 2002, ed. M. Brin, et al., Pub.—Lippincott Williams & Wilkins, p. 11-27.
Harrison's principles of internal medicine, 14thEdition, ed. by Fauci, et al., (1998), Table of Contents.
Hoogerwerf, W., et al.,Botulinum toxin for spastic gastrointestinal disorders, Bailliere's Clin Gastroentero 1999;13(1):131-143.
Kohl, A., et al.,Comparison of the effect of botulinum toxin A(Botox®)with the high-purified neurotoxin(NT 201)in the extensor digitorum brevis muscle test, MovDisord 2000;15(Suppl 3):165.
Kondo, T., et al.,Modification of the action of pentagastrin on acid secretion by botulinum toxin, Experientia 1977;33:750- 1.
Laskawi, R., et al.,Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating(Frey's Syndrome), Laryngoscope 1998 Mar.;108(3):381-4.
Marjama-Lyoas, J., et al.,Tremor-predominant Parkinson's disease, Drugs & Aging 2000 Apr.; 16(4):273-278.
Marchese-Ragona, R., et al.,Management of parotid siatocele with botulinum toxin, Laryngoscope 1999 Aug.;109(8):1344-1346.
Meyer, K.E.,A comparative systemic toxicity study of neurobloc in adult and juvenile cynomolgus monkeys, Mov Disord 2000;15(Suppl 2):54.
Naumann, M., et al.,Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, Euro. J. Neurology, 1999, 6 suppl 4:S111-S115.
Pearce, L. B., et al.,Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412.
Rossi, S., et al.,Immunohistochemical localization of SNAP-25 protein in the stomach of rat, Naunyn Schmiedebergs Arch Pharmacol, 2002;365(Suppl 2):R37.
Allergan Inc.
Donovan Stephen
Kam Chih-Min
Nassif Claude L.
Voet Martin A.
LandOfFree
Methods for treating ulcers and gastroesophageal reflux disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating ulcers and gastroesophageal reflux disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating ulcers and gastroesophageal reflux disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3741223